Tuesday, April 2 12–1:15pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 1)
Tuesday, April 2 1:30–3:45pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 2)
Tuesday, April 2 9:30–10:30am
Alzheimer Disease in Primary Care: Early Identification and New Anti-Amyloid Treatment Options
Tuesday, April 2 12–1:15pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 1)
Tuesday, April 2 1:30–3:45pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 2)
Tuesday, April 2 4–5:30pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Tuesday, April 2 12–1:15pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 1)
Tuesday, April 2 1:30–3:45pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 2)
Wednesday, April 3 8:15–9am
Curbside Consults: Top Questions from PCPs on End of Life and Palliative Care
Tuesday, April 2 10:30–11:30am
Two Sides of the Same Coin: A Dual-Focused Approach for Diabetes and Weight Management
Wednesday, April 3 7:30–8:15am
Cancer Demographics, Screening, and Differences in African Americans
Tuesday, April 2 9:30–10:30am
Alzheimer Disease in Primary Care: Early Identification and New Anti-Amyloid Treatment Options
Wednesday, April 3 12:30–1:30pm
Spotting the Difference: Common Dermatologic Rashes and Infections
Wednesday, April 3 2:30–3:15pm
Curbside Consults: Top Questions from PCPs on Responsible Antibiotic Prescribing
Wednesday, April 3 10–11am
Multi-Cancer Early Detection: Overcoming Barriers to Cancer Screening
Tuesday, April 2 10:30–11:30am
Two Sides of the Same Coin: A Dual-Focused Approach for Diabetes and Weight Management
Tuesday, April 2 4–5:30pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Wednesday, April 3 11am–12pm
Preventive Cardiology: A Roadmap for Primary Care Clinicians
Wednesday, April 3 10–11am
Multi-Cancer Early Detection: Overcoming Barriers to Cancer Screening
Disclosures
The following financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Relevant relationships will be disclosed at the start of each presentation.
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel Pharmaceuticals, Kowa Pharmaceuticals America, Lilly, Lundbeck, Nevro, and Teva., Speaker; AbbVie, Amgen, Averitas Pharma, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Tremeau Pharmaceuticals, Tris Pharma, Vertex and Xgene Pharma., Advisor; AbbVie, Amgen, Lilly, Lundbeck, and Teva., Researcher; Neumentum, PainScript, and Tris Pharma, Consultant; Pfizer and Trevena., Stock Holder (publicly traded company)
- Amy Clouse, MD, FAAFP
- Astellas Pharma, Advisor; Astellas Pharma, Speaker
- Oscar A. de Leon-Casasola, MD
- Kowa Pharmaceuticals, Advisor; Kowa Pharmaceuticals, Consultant
- Lisa M. Ferreira, MD, FOMA
- Elil Lill and Novo Nordisk, Inc., Speaker; Novo Nordisk, Speaker
- Katherine E. Galluzzi, DO, CMD, FACOFP
- No relevant financial relationships disclosed.
- Jennifer B. Green, MD
- Boehringer Ingelheim, Researcher; Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim, Consultant
- Gregory L. Hall, MD
- No relevant financial relationships disclosed.
- Lawrence Herman, DMSc, MPA, PA-C, DFAAPA
- Novo Nordisk, Speaker
- Pallavi Joshi, DO, MA
- No relevant financial relationships disclosed.
- Jonette Keri, MD, PhD
- Almirall, Advisor; L'Oreal, Advisor; Ortho Dermatologics, Advisor; Primus Pharmaceuticals, Advisor
- Pamela Kushner, MD, FAAFP
- Abbott, Stock Holder (publicly traded company); Janssen, Lilly/BI, AstraZeneca, GlaxoSmithKline, Phathom, Astellas, Haleon, and Novo Nordisk., Speaker; Lilly, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Corcept, Haleon, and Bayer., Consultant; Novo Nordisk, Lilly, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Abbott, Phathom, Bausch/SALIX, Intuity, Pfizer, and Janssen., Advisor
- Paola Lichtenberger, MD
- No relevant financial relationships disclosed.
- Mylynda B. Massart, MD, PhD
- GRAIL, LLC, Speaker
- Charles Vega, MD, FAAFP
- GlaxoSmithKline and Boehringer Ingelheim, Consultant
- Karol E. Watson, MD, PhD
- Amarin, Consultant; Amgen, Consultant; Boehringer Ingelheim, Consultant; Lilly, Consultant; Novartis, Consultant
- Candace Westgate, DO, MPH, FACOG
- GRAIL, LLC and Myriod Genetics, Consultant; GRAIL, LLC and Myriod Genetics, Speaker
Other Disclosures
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.